[7]Subbiah V, Gervais R, Riely G, et al. Efficacy of Vemurafenib in patients with non-small-cell lung cancer with BRAF V600 mutation: An open label, single-arm cohort of the histology-independent VE-BASKET study. JCO Precis Oncol, ...
At present, there are many clinical trials on BRAF⁃mutation NSCLC and new drugs constantly emerging. However, there is no standardized consensus on the diagnosis and treatment of BRAF⁃mutation NSCLC in China. The expert group of the Lung Cancer Professional Committee of the Chinese Anti⁃...
[5]Odogwu L, Mathieu L, Blumenthal G,et al. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations. Oncologist. 2018 Jun;23(6):740-745. doi: 10.1634/theonco...
IMPLICATIONS FOR PRACTICE: Personalized medicine has begun to provide substantial benefit to patients with oncogene-driven non-small cell lung cancer (NSCLC). However, treatment options for patients with oncogenic driver mutations lacking targeted treatment strategies remain limited. Direct inhibition of ...
[5]Odogwu L, Mathieu L, Blumenthal G,et al. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations. Oncologist. 2018 Jun;23(6):740-745. doi: 10.1634/theoncologist.2017-0642. ...
随着对肿瘤分子水平研究的不断深入,BRAF突变已被确定为各种恶性肿瘤生长的驱动因素,其中BRAF V600突变在肺癌中占2%-4%。临床对于携BRAF突变非小细胞肺癌(NSCLC)的治疗,使用传统的化疗或新型的免疫治疗,疗效获益有限,而达拉非尼+曲美替尼(简称“D+T”)方案是针对BRAF突变晚期NSCLC患者的首个双靶药物,已得到国内外...
[5]Odogwu L, Mathieu L, Blumenthal G,et al. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations. Oncologist. 2018 Jun;23(6):740-745. doi: 10.1634/theoncologist.2017-0642. ...
[2]Yan N, Guo S, Zhang H, et al. BRAF-mutated non-small cell lung cancer: Current treatment status and future perspective[J]. Frontiers in Oncology, 2022, 12: 863043. [3]Planchard D, Smit E F, Groen H J M, et al. Dabrafenib plus trametinib in patients with previously untreated BR...
[5]Odogwu L, Mathieu L, Blumenthal G,et al. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations. Oncologist. 2018 Jun;23(6):740-745. doi: 10.1634/theoncologist.2017-0642. ...
1. Facchinetti F, Lacroix L, Mezquita L, et al. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF non-small cell lung cancer. Eur J Cancer, 2020, 132: 211-223. 2. Dagogo-Jack I, Martinez P, Yeap BY, et al. Impact of BRAF Mutation Class on Disease Characteristics...